Monday, July 15, 2024
HomeClinical Trials and ResearchUpcoming investigation into potential new metastatic breast cancer treatment

Upcoming investigation into potential new metastatic breast cancer treatment

PrECOG and Oncolytics Biotech announce a joint study into the use of pelareorep in the treatment of metastatic breast cancer.

It was recently announced that two companies, PrECOG and Oncolytics Biotech, would be collaborating on a new study in the field of cancer research. The two groups are preparing to begin conducting a new study, the BRACELET-1 (PrE0113) study, for metastatic breast cancer. This proposed study is unique in that the researchers are planning to use the “safe and well-tolerated” virus, pelareorep, to investigate how it can be involved in the treatment of metastatic breast cancer – that is, breast cancer that has spread to other areas of the body. The specific subtype of metastatic breast cancer that the researchers are planning to study the effect of pelareorep treatment on is, ‘hormone receptor-positive metastatic breast cancer’. This type of breast cancer simply means that the cancer cells have receptors for either, or both, of the hormones estrogen and progesterone.

Importance of the study

The virus, pelareorep, that the researchers at Oncolytics Biotech are developing, is a safe biological agent that would be injected into a patient’s veins. Pelareorep would work to make the tumour cells recognizable to our body’s immune system so that the cells can be killed. Administration of the virus would make the tumours sensitive to a potential variety of treatment combinations, which would hopefully improve patient outcomes. Immunotherapy, “a type of treatment that helps the immune system fight cancer”, is still in the early stages as a possible treatment option for breast cancer. But, hopefully successful results from this proposed study can help move this treatment option forward, as a viable option for patients with hormone receptor-positive cancers.

Details of the study design are being finalized and will then be sent to the FDA for approval. If all goes well, enrollment of patients to the study will begin in 2020.

 

Written by Haritha Thevar, BSc

 

References:

Cancer cells. (2019). Retrieved 26 October 2019, from https://www.cancerresearchuk.org/about-cancer/what-is-cancer/how-cancer-starts/cancer-cells

Immunotherapy for Cancer. (2019). Retrieved 26 October 2019, from https://www.cancer.gov/about-cancer/treatment/types/immunotherapy

Oncolytics Biotech, Inc. (ONCY). (2019). Retrieved 26 October 2019, from https://www.oncolyticsbiotech.com/

Oncolytics Biotech® and PrECOG announce study in metastatic breast cancer. (2019). Retrieved 26 October 2019, from https://www.eurekalert.org/pub_releases/2019-10/ecrg-oba102119.php

What is breast cancer?. (2019). Retrieved 26 October 2019, from https://www.cancer.ca/en/cancer-information/cancer-type/breast/breast-cancer/?region=on

Metastatic Cancer – What is Metastasis? Diagnosing and Treating. (2019). Retrieved 26 October 2019, from https://www.cancercenter.com/metastasis

Image by marijana1 from Pixabay

 

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

Prevalence of long COVID rises to nearly 7% of population

US government number crunchers published a briefing article in JAMA1, June 7, 2024, presenting the results of their latest round of analysis on long...

Joke Of The Day

Did you hear about the guy who had his whole left side cut off? He's all right now...

ADVERTISE WITH US

error: Content is read-only and copy-protected.